Introduction

Attentional deficits and exaggerated impulsivity are core features of several psychiatric disorders, including attention-deficit/hyperactivity disorder, schizophrenia, and addiction (American Psychiatric Association, 2013). The brain dopamine (DA) system is known to be involved in the psychopathology of these disorders (Everitt and Robbins, 2005; Franken et al, 2005; Howes and Kapur, 2009; Tripp and Wickens, 2009; Volkow and Baler, 2015), as well as in the regulation of attention and impulsivity (Bari and Robbins, 2013; Cools, 2011; Nieoullon, 2002; Pattij and Vanderschuren, 2008). However, the relationship between DA signaling, attention, and impulse control remains incompletely understood. Previous research has mainly focused on DA signaling in target areas such as the striatum and prefrontal cortex (PFC). DA signaling in these areas depends on DA neuronal activity in the midbrain, but it is unknown whether abnormal activity of DA neurons underlies attentional deficits and/or impulsivity.

Here, we took a novel approach by testing the impact of chemogenetic activation of midbrain DA neurons on attentional performance and impulsive behavior in rats. We used designer receptors exclusively activated by designer drugs (DREADD; Armbruster et al, 2007) in TH::Cre transgenic rats, to selectively increase DA neuronal activity in either the ventral tegmental area (VTA) or substantia nigra pars compacta (SNc). The effects on attention and impulsivity were tested in the five-choice serial reaction time task (5-CSRTT; Carli et al, 1983). In this task, the rats are trained to respond to a visual stimulus, which is briefly and pseudo-randomly presented in one of five nose-poke holes. Impulsivity in the 5-CSRTT is measured by assessing premature responses that are made before the stimulus onset. Elevated DA signaling in the striatum, especially the nucleus accumbens (NAc) and dorsomedial striatum (DMS), has been associated with premature responding (Agnoli et al, 2013; Baarendse and Vanderschuren, 2012; Economidou et al, 2012; Van Gaalen et al, 2006; Moreno et al, 2013; Pattij et al, 2007; Pezze et al, 2007). Attentional performance is tested by assessing response accuracy and trial omissions, which are mainly affected by DAergic manipulations in the PFC and dorsal striatum (Agnoli and Carli, 2011; Agnoli et al, 2013; Baunez and Robbins, 1999; Economidou et al, 2012; Granon et al, 2000; Rogers et al, 2001; Winstanley et al, 2010). These findings suggest a role for both the mesocorticolimbic and nigrostriatal DA pathway—ascending from DA neurons in VTA and SNc, respectively (Bjorklund and Dunnett, 2007; Moore and Bloom, 1978)—in the regulation of attention and impulsivity. In this study, we tested whether enhanced midbrain DA neuronal activity is sufficient to induce attentional deficits and/or impulsive actions in rats. As pharmacological stimulation of DA signaling, via DA receptor (DA-R) agonists or DA reuptake inhibition, has repeatedly been shown to promote impulsive actions (Agnoli et al, 2013; Baarendse and Vanderschuren, 2012; Economidou et al, 2012; Van Gaalen et al, 2006; Moreno et al, 2013; Pattij et al, 2007; Pezze et al, 2007), we hypothesized that chemogenetic activation of midbrain DA neurons would increase premature responding. Given the major role of the NAc and DMS in impulsivity (Dalley et al, 2011; Eagle and Baunez, 2010), we predicted that particularly VTA DA neuron activation would enhance impulsive actions, whereas SNc DA neuron activation would have a more modest effect. Attentional performance in the 5-CSRTT has been shown to either be improved or impaired following the administration of DA-R agonists and DA reuptake inhibition (Agnoli et al, 2013; Baarendse and Vanderschuren, 2012; Besson et al, 2010; Economidou et al, 2012; Granon et al, 2000; Pezze et al, 2007; Winstanley et al, 2010). Therefore, we hypothesized that activation of DA neurons in either VTA or SNc would affect attentional accuracy and trial omissions, although the directionality of the effects was not readily predictable.

Materials and methods

Animals

Male TH::Cre+/− rats were bred in-house, by crossing heterozygous TH::Cre+/− rats with wild-type Long Evans mates. In total, 42 rats were used, divided into three groups: (1) VTA:Dq+, n=12 Cre+/− rats, with DREADD in the VTA; (2) SN:Dq+, n=16 Cre+/− rats with DREADD in the SNc; and (3) Cre−, n=14, a control group of Cre−/− littermates, which received DREADD virus in the VTA, but do not express Cre and thus do not express DREADD. In each behavioral test, the effects of clozapine-N-oxide (CNO) were compared with saline control treatment in each animal. A Cre-negative group was included to control for potential effects of CNO administration in the absence of DREADD expression. To reduce the number of animals used in this study, we have included a single Cre-negative control group, infused with Cre-dependent DREADD virus in the VTA. Earlier (pilot) studies have shown that infusion of DREADD virus into the SNc in Cre-negative rats did not result in any DREADD expression, nor did we observe any behavioral effects of CNO administration. The rats were socially housed in Macrolon type III or IV cages, in a temperature- and humidity-controlled room. A wood block was provided for cage enrichment. The rats were housed under a reversed 12 h day–night cycle (lights on at 19 : 00), allowing behavioral training and testing during the animals’ active phase. The rats had ad libitum access to water. Throughout the experiment, the rats were food restricted to maintain 90% of their free-feeding body weight. All the experiments were approved by the Animal Ethics Committee of Utrecht University and were conducted in accordance with Dutch laws (Herziene Wet op Dierproeven, Art 10.a.2, 2014) and European regulations (Guidelines 86/609/EEC and 2010/63/EU).

Surgery

All the animals were injected bilaterally with 1 μl of AAV5-hSyn-DIO-hM3Dq-mCherry (6.4–8.0 × E12 molecules/ml; UNC Vector Core), using a stereotactic apparatus. The surgery was performed in two cohorts, one before operant training (n=22, 7 weeks old, ~200 g), and one after training (n=20, 27 weeks old, ~450 gram). For the first cohort, coordinates for VTA were set at AP: −5.4, ML: +1.3 (5° angle), DV: −8.0 mm; and SNc at AP: −5.2, ML: +2.0, DV: −7.2. The second cohort received VTA injections at AP: −5.8, ML: +1.3 (5° angle), DV: −8.4; and SNc at AP −5.4, ML +2.2, DV −7.7. All the coordinates are in millimeters relative to Bregma. The virus was infused at a rate of 0.2 μl/min for 5 min, and the needle was left in place for 10 min after infusion. The surgery was performed under anesthesia, induced by intramuscular fentanyl/fluanisone (0.315 mg/kg fentanyl, 10 mg/kg fluanisone; Hypnorm, Janssen Pharmaceutical). Local anesthesia was provided by xylocaine, sprayed on the skull (Lidocaine 100 mg/ml, AstraZeneca BV). Carprofen (5.0 mg/kg, subcutaneously, Carporal, AST Farma BV) was given for pain relief, at the day of surgery and the two following days. The rats were housed individually for 1 week under DM-II conditions, to recover from surgery. There were at least 8 weeks in between surgery and behavioral testing.

Five-Choice Serial Reaction Time Task

Behavioral training and testing on the 5-CSRTT were performed as previously published (Baarendse and Vanderschuren, 2012), with slight adjustments. All the training and testing took place in operant conditioning chambers (30.5 × 24 × 21 cm, Med-Associates, USA), placed in sound attenuated boxes, and controlled by MED-PC version IV (Med-Associates). The chambers were equipped with five evenly spaced nose-poke holes in a curved wall, each with a yellow light-emitting diode stimulus light and an infrared detector, and a food magazine for pellet delivery in the opposite wall. Following habituation to the setup, the rats were trained to respond to an illuminated nose-poke hole, which was rewarded with delivery of a sucrose pellet (45 mg, TestDiet, USA) in the food magazine. Over six different training stages, the rats learned to perform this task under baseline conditions of 5 s intertrial interval (ITI), 1 s stimulus duration (SD) and 5 s limited hold.

All the sessions started with the delivery of a free sucrose pellet into the food magazine, after which the rat could initiate a trial by nose-poking into the food magazine. Each trial started with a 5 s ITI, before a stimulus light was presented in one of the five nose-poke holes, in a pseudo-random order. When a correct response was made, ie, a nose-poke in the illuminated hole within the limited hold period, a sucrose pellet was delivered. A response in one of the other four holes was recorded as an incorrect response, a failure to respond within the limited hold period as an omission, and a nose-poke made during the ITI as a premature response. Incorrect responses, omissions, and premature responses were punished with a 5 s time-out, during which stimulus lights were switched off and the house light was switched on. Repeated responses in one of the nose-poke holes were recorded as perseverative responses, but had no programmed consequences. Latencies to respond (premature, correct, incorrect, and food magazine entry) were recorded as well. The next trial started either when the animal entered the food magazine to collect the reward, or automatically after a time-out. The sessions lasted for 100 trials or 30 min, whichever occurred first. For analysis, omissions were defined as the percentage of omitted trials relative to total number of trials (omissions/[correct+incorrect+omissions] × 100%). The number of omissions following either a correct response or a time-out were calculated from trial-by-trial data, and analyzed as percentage of total omissions, to correct for any changes in total number of omitted trials. Accuracy was defined as percentage of correct responses relative to total responses (correct/[correct+incorrect] × 100%). Other parameters were analyzed as absolute values.

Pharmacological testing started after approximately 3 months, when the rats showed stable baseline performance levels. Task performance was tested 30 min after administration of selective DREADD ligand CNO or saline, using a within-subject, counter-balanced design. Challenge sessions were separated by at least two baseline training sessions (5 s ITI, 1 s SD). Dose-response testing for CNO was conducted using a Latin Square design, with at least one wash-out baseline day between test sessions.

Drugs

CNO (kindly provided by Bryan Roth (University of North Carolina, Chapel Hill NC, USA)) and the NIMH Chemical Synthesis and Drug Supply Program) and d-amphetamine sulphate (OPG Utrecht, The Netherlands) were dissolved in sterile 0.9% saline and kept at 4 °C in between testing. All the injections were given intraperitoneally, at 1 ml/kg bodyweight. CNO was given at a dose of 0.3 mg/kg, unless stated otherwise. This dose was chosen based on previous work, in which we showed that 0.3 mg/kg yielded significant behavioral effects (ie, increased locomotor activity) in rats expressing hM3Dq in DA neurons in either VTA or SNc (Boekhoudt et al, 2016).

Tissue Preparation and Immunohistochemistry

Killing, tissue preparation, and immunohistochemical analysis were performed as previously described (Boender et al, 2014). The rats received a lethal dose of sodium pentobarbital (0.1 ml/100 g bodyweight; Euthanimal, Alfasan BV, The Netherlands), and were transcardially perfused with 0.9% saline followed by 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS). The brain slices (40 μm) were stained for tyrosine hydroxylase (TH) and hM3Dq-mCherry with Mouse anti-TH (EMD Millipore, 1 : 500) and Rabbit anti-dsRed (Clontech, 1 : 500), respectively. Overnight incubation (at 4 °C) with these primary antibodies was followed by 2 h incubation with secondary antibodies Goat anti-Rabbit 568 (1 : 500) and Goat anti-Mouse 488 (Molecular Probes, 1 : 1000). All the antibodies were dissolved in PBS containing 0.05% Tween. The slices were mounted with FluorSave (EMD Millipore).

Quantification of DREADD Expression

Fluorescent pictures were taken using a Zeiss Axio Scope A1 microscope and AxioVision software, with identical settings for all animals. Intensity of hM3Dq-mCherry fluorescence in midbrain and striatum was analyzed using ImageJ. Fluorescence intensity (0–255, arbitrary units) was measured at selected sub-regions in the midbrain (VTA and dorsal part of SNc (SNcd) −5.2 to −6.0 mm from Bregma; medial part of SNc (SNm) −5.6 to −6.0 mm from Bregma) and striatum (NAc Core, NAc Shell, DMS, dorsolateral striatum (DLS), 2.0 to 1.0 mm from Bregma). mCherry fluorescence was not detectable in other DAergic target regions, including the PFC. Background fluorescence (measured at peri-acquaductal grey for midbrain and insular cortex for striatum) was subtracted from the measurements, and average fluorescence intensity was calculated per animal (two to eight measurements per region).

Data Analysis

Fluorescence levels per region were compared between groups using Newman–Keuls test, followed by post hoc Mann–Whitney U-tests (P-value corrected for multiple comparisons). In total, 6–10 rats were included for the Cre− control group and 13–15 rats for VTA:Dq+ and SN:Dq+ groups.

No animals were excluded from the analysis on the basis of DREADD expression. For behavioral analysis, the rats were included based on baseline performance criteria (20% omissions and 85% accuracy). One rat in the SN:Dq+ group did not meet these criteria and was excluded from all the analyses. Furthermore, the animals were excluded from analysis of specific tests when baseline performance before drug administration did not meet the selection criteria. In total, 12–15 animals per group were included for each behavioral analysis. Effects of CNO compared with saline were tested using repeated-measures general linear model (RM-GLM). When RM-GLM indicated a significant interaction between experimental Group (VTA:Dq+/SN:Dq+/Cre−) and Treatment (CNO/saline), post hoc pairwise comparisons were performed per group. Exploratory studies for the effects of amphetamine or a 7 s ITI were analyzed by paired samples t-tests. Effects of challenges compared with baseline conditions were tested with RM-GLM, using only data from saline test days, and post hoc tests were performed following either a significant main effect of Challenge, or Challenge × Group interaction. Dose-response analysis of CNO was tested with RM-GLM. On the basis of Mauchly’s test of sphericity, degrees of freedom were adjusted according to Huyn–Feldt correction (when Huyn–Feldt epsilon 0.7) or Greenhouse–Geisser (when Huyn–Feldt epsilon <0.7). Statistical significance was set at α=0.05, and Bonferroni corrections were made for multiple comparisons. Statistical tests were performed using SPSS 16.0 and graphs were made using GraphPad Prism 6 and Adobe Illustrator.

Results

DREADD Expression

All the rats were injected with Cre-dependent DREADD virus (AAV-hSyn-DIO-hM3Dq-mCherry) in either the VTA or SNc (Figure 1a). Immunohistochemical analysis confirmed DREADD expression in the VTA in VTA:Dq+ rats, and in SNc in SN:Dq+ rats. (Figure 1a). To quantify expression levels in midbrain as well as striatum, mCherry fluorescence intensity was measured in specific sub-regions (Figure 1a and b). This revealed that the VTA:Dq+ group primarily expressed DREADD in the VTA and SNm (fluorescence levels both P<0.0015 compared with Cre−), and also showed modest expression in SNcd (P=0.015 compared with Cre−; Figure 1a). This was reflected in the striatum by DREADD expression primarily in NAc Core and Shell, as well as DMS, and to a lesser extent DLS (Figure 1b; all P<0.01 compared with Cre−). In contrast, the SN:Dq+ group primarily showed DREADD expression in SNm and SNcd, as well as modest expression in VTA (all P<0.0015 compared with Cre−). In the striatum, this was reflected by expression primarily in DLS, as well as DMS and NAc Core (Figure 1b). Compared with the VTA:Dq+ group, the SN:Dq+ group showed significantly higher expression levels in SNcd and DLS, but lower expression in NAc Shell (Figure 1a and b). Thus, VTA:Dq+ rats mainly showed DREADD expression in the mesolimbic pathway, including projections to NAc and DMS, whereas SN:Dq+ rats mainly showed expression in the nigrostriatal pathway, towards dorsal striatum.

Figure 1
figure 1

DREADD expression in DA neurons in VTA or SNc. DREADD expression in midbrain (a) and striatal projection areas (b). All the rats received bilateral injection with Cre-dependent DREADD virus into VTA or SNc (a, top left). Red rectangle represents area depicted in lower panels, showing representative examples of expression of tyrosine hydroxylase (TH) and DREADD (hM3Dq-mCherry) in midbrain and striatum of TH::Cre rats expressing DREADD in the VTA (VTA:Dq+) or SNc (SN:Dq+). Top right panels show quantified fluorescence levels in selected sub-regions in the midbrain and striatum. Error bars represent mean±SEM *P<0.05, **P<0.01 difference compared with Cre− control group. $$P<0.01 difference between VTA:Dq+ and SN:Dq+ groups.

PowerPoint slide

The rats operated in the second cohort showed higher intensity of DREADD expression compared with the first cohort, which is likely due to the use of a different virus batch. As behavioral effects of CNO did not differ between cohorts, the results were pooled for statistical analysis.

Effects of DA Neuron Activation on Attention

Chemogenetic activation of DA neurons impaired attentional performance in the 5-CSRTT under baseline conditions. In both VTA:Dq+ and SN:Dq+ rats, omissions were increased after CNO treatment (Figure 2a; Group × Treatment interaction F2,37=5.4, P=0.009; post hoc VTA:Dq+ and SN:Dq+, both P<0.0005). Furthermore, CNO treatment decreased accuracy in the SN:Dq+ group (Figure 2b; Group × Treatment interaction F2,37=10.432, P<0.0005; post hoc SN:Dq+ P<0.0005). These attentional deficits were also reflected in a decreased number of correct responses in both VTA:Dq+ and SN:Dq+ groups (Table 1, Group × Treatment interaction F2,37=6.08, P=0.005, post hoc VTA:Dq+ and SN:Dq+, both P<0.0005), and an increased number of incorrect responses in the SN:Dq+ group (Table 1, Group × Treatment interaction F2,37=4.998, P=0.012, post hoc SN:Dq+ P=0.003). Perseverative responses were not affected by CNO treatment (Table 1, Group × Treatment interaction F2,37=1.818, P=0.177).

Figure 2
figure 2

Chemogenetic activation of VTA or SNc DA neurons impairs attentional performance. (a) CNO increased number of omissions in VTA:Dq+ and SN:Dq+ group. (b) CNO decreased accuracy in SN:Dq+ group. (c) CNO increased latency to make an incorrect response in SN:Dq+ group to >1.0 s (dotted line, represents stimulus duration, SD). (d) Shorter SD decreased accuracy compared with baseline (left panel). CNO decreased accuracy in SN:Dq+ group, also with 0.5 or 2 s SD. (e) Longer SD decreased omissions compared with baseline. CNO increased number of omissions in VTA:Dq+ and SN:Dq+ groups, also with 0.5 or 2 s SD. Error bars represent mean±SEM *P<0.05, **P<0.01, ***P<0.001.

PowerPoint slide

Table 1 Effects of Chemogenetic Activation of VTA or SNc DA Neurons on Performance in 5-CSRTT

In addition, CNO treatment affected the rats’ response latencies, with differential effects in the VTA:Dq+ and SN:Dq+ group. CNO reduced the reward collection latency in VTA:Dq+ rats, whereas this was increased in SN:Dq+ rats (Table 1, Group × Treatment interaction F2,37=10.186, P<0.0005; post hoc VTA:Dq+ P=0.009, SN:Dq+ P=0.001). SN:Dq+ rats also showed a delayed latency to make correct or incorrect responses, whereas this was unaffected in VTA:Dq+ rats (Table 1 and Figure 2c, Group × Treatment interaction correct latency F2,37=12.022, P<0.0005, post hoc SN:Dq+ P<0.0005, VTA:Dq+ P=0.147; incorrect latency F2,37=3.654, P=0.036, post hoc SN:Dq+ P=0.025, VTA:Dq+ P=0.188).

To test whether the attentional deficits caused by CNO were dependent on attentional load, we tested the animals with a shorter (0.5 s) and longer SD (2 s). Indeed, SD affected the attentional performance: a shorter SD decreased the accuracy (Figure 2d; effect of SD F1.57;32.28=19.603, P<0.0005; post hoc tests 0.5 s SD vs baseline P=0.001; 2 s SD vs baseline P=0.069), whereas a longer SD decreased omissions (Figure 2e; effect of SD F1.81;61,60=14.819, P<0.0005; post hoc tests 0.5 s SD vs baseline P=0.066; 2 s SD vs baseline P=0.009). However, the effect of CNO in SN:Dq+ or VTA:Dq+ rats was not affected by these changes in SD. Similar to baseline conditions, CNO decreased accuracy in the SN:Dq+ group (Figure 2d; 0.5 s SD F2,39=10.103, P<0.0005, post hoc SN:Dq+ P<0.0005; 2 s SD F2,35=4.935, P=0.013, post hoc SN:Dq+ P=0.001), and increased omissions in both VTA:Dq+ and SN:Dq+ groups (Figure 2e; 0.5 s SD F2,39=7.559, P=0.002, post hoc VTA:Dq+ and SN:Dq+, both P<0.0005; 2 s SD F2,35=7.343, P=0.002, post hoc VTA:Dq+ P=0.002, SN:Dq+ P<0.0005). With saline treatment, one-third (33±3.6%) of omissions occurred following a time-out—as opposed to 67% following a correct response. Although the percentage omissions made after a time-out was somewhat higher in VTA:Dq+ and SN:Dq+ groups following CNO treatment (49±7.2% and 56±5.0%, respectively), this difference did not reach statistical significance (Group × Treatment interaction F2,36=2.138, P=0.133).

In summary, chemogenetic activation of DA neurons in either VTA or SNc significantly impaired attention, which was not dependent on attentional load. In VTA:Dq+ rats, CNO treatment increased omissions, while in SN:Dq+ rats, CNO treatment increased omissions and decreased accuracy. Furthermore, activation of VTA DA neurons decreased latency to collect rewards, whereas SNc DA neuron activation increased latency to collect rewards, and to make correct and incorrect responses.

Effects of DA Neuron Activation on Impulsivity

Under baseline conditions, CNO treatment did not affect the number of premature responses (Figure 3a; Group × Treatment interaction F2,37=2.351, P=0.109), nor the latency to make a premature response (Figure 3b; Group × Treatment interaction F2,37=1.050, P=0.360).

Figure 3
figure 3

Chemogenetic activation of VTA or SNc DA neurons does not affect premature responses. No significant effect of CNO vs saline on the number of premature responses (a) or latency to make premature response (b). (c) Systemic injections of amphetamine (0.3 or 1.0 mg/kg), or prolonged intertrial interval of 7 s (7 s ITI) increased the number of premature responses. (d) Total number of premature responses was increased by challenges with longer ITI (7 s ITI or variable long ITI compared with baseline), but was not affected by CNO. (e) Latency to make premature responses was increased by challenges with longer ITI (7 s ITI or variable long ITI compared with baseline), and decreased by CNO in VTA:Dq+ and SN:Dq+ group. Error bars represent mean±SEM *P<0.05, **P<0.01, ***P<0.001.

PowerPoint slide

As a positive control for enhancement of impulsivity, we tested the effects of systemic amphetamine (AMPH) administration, or testing with a longer ITI of 7 s (7 s ITI). Both manipulations have been reported to increase premature responding in the 5-CSRTT (Baarendse and Vanderschuren, 2012; Cole and Robbins, 1989; Dalley et al, 2007; Van Gaalen et al, 2006). We found that, as expected, both AMPH and a longer ITI increased the number of premature responses (Figure 3c; 0.3 mg/kg AMPH vs Sal t11=−2.434, P=0.033; 1.0 mg/kg AMPH vs Sal t11=−2.603, P=0.025; 7 s ITI vs 5 s ITI t12=−4.951, P<0.0005; negative control Sal vs Sal t10=−1.33, P=0.213).

Next, we tested whether CNO would affect impulsive behavior under conditions of increased impulsivity, ie, during a 7 s ITI, or variable long ITIs, varying from 5 to 15 s (vITI). We found that longer ITIs profoundly increased the number of premature responses under saline conditions (Figure 3d; main effect of ITI F2,70=82.431, P<0.0005; post hoc comparisons all P<0.0005). With longer ITIs, also the latency to make a premature response was increased (Figure 3e; main effect of ITI F1.7;58.3=140.446, P<0.0005; post hoc comparisons all P<0.0005). However, similar to baseline conditions, treatment with CNO did not affect the number of premature responses (Figure 3d; Group × Treatment interaction 7 s ITI: F2,37=0.045, P=0.956; vITI: F2,39=0.9, P=0.415). CNO did significantly decrease the latency to make a premature response, in the VTA:Dq+ group both under 7 s ITI and vITI conditions, and in the SN:Dq+ group under the vITI condition (Figure 3e; Group × Treatment interaction 7 s ITI: F2,37=3.778, P=0.032, post hoc VTA:Dq+ P=0.003; vITI: F2,39=4.872, P=0.013, post hoc VTA:Dq+ P=0.003, SN:Dq+ P=0.025).

In summary, chemogenetic activation of DA neurons in VTA or SNc did not affect the number of premature responses—either under baseline conditions or during challenges with prolonged ITIs. DA neuron activation did reduce the latency to make a premature response, both in VTA:Dq+ and SN:Dq+ rats, especially during prolonged ITIs.

Dose-Dependent Effects of CNO on Attention

To determine the dose-dependency of the effects of CNO, we tested five different doses, under baseline conditions (5 s ITI, 1 s SD). Consistent with our earlier results, we found no significant effect of CNO on premature responding (Figure 4a; Group × Treatment interaction F7.5;135.3=1.239, P=0.284). CNO dose-dependently increased omissions in both VTA:Dq+ and SN:Dq+ groups (Figure 4b; Group × Treatment interaction F6.0;107.8=9.551, P<0.0005). In the SN:Dq+ group, CNO increased omissions at 0.03 mg/kg and higher (CNO vs saline P=0.001; 0.1 and 0.3 mg/kg, both P<0.001); whereas in the VTA:Dq+ group, only the highest dose (0.3 mg/kg) significantly increased omissions (CNO vs saline P=0.004). In SN:Dq+ rats, doses of 0.03 mg/kg and higher also decreased accuracy (Figure 4c; Group × Treatment interaction F4.6;82.7=5.515, P<0.0005; SN:Dq+ 0.03, 0.1 and 0.3 mg/kg CNO vs saline, all P<0.01), whilst response latency was increased at 0.1 and 0.3 mg/kg CNO (Figure 4d; Group × Treatment interaction F4.2;74.8=5.643, P<0.0005; SN:Dq+ 0.1 and 0.3 mg/kg CNO vs saline, both P<0.001). No significant effects were found on the latency to collect the reward (Figure 4e; Group × Treatment interaction F3.4;61.1=1.778, P=0.154) or the latency to make a premature response (Figure 4f; Group × Treatment interaction F8;144=1.311, P=0.242). Thus, low doses of CNO (0.03 mg/kg and higher) were sufficient to impair attention in SN:Dq+ rats, while only the highest dose tested (0.3 mg/kg) significantly affected attention in VTA:Dq+ rats.

Figure 4
figure 4

Dose-dependent effects of CNO on 5-CSRTT performance. (a) Premature responses were not affected by CNO. (b) Omissions were increased at 0.03 mg/kg CNO and higher doses in SN:Dq+ group, and at 0.3 mg/kg CNO in VTA:Dq+ group. (c) Accuracy was decreased at 0.03 mg/kg CNO and higher doses in SN:Dq+ group, and unaffected in VTA:Dq+ group. (d) Latency to make a correct response was increased at 0.1 and 0.3 mg/kg CNO in SN:Dq+ group, and unaffected in VTA:Dq+ group. (e and f) Latency to collect the reward and latency to make a premature response were not significantly affected by CNO. Error bars represent mean±SEM **P<0.01, ***P<0.001 CNO compared with saline (0 mg/kg CNO).

PowerPoint slide

Discussion

In this study, we show that chemogenetic activation of VTA and SNc DA neurons impairs attentional performance in the 5-CSRTT. In contrast, we found no evidence for increased impulsivity as a result of enhancing midbrain DA neuron activity. In addition, we show that DA neuronal activation in the VTA compared with SNc results in a distinct behavioral profile with respect to attentional accuracy and response latency. Although increasing DA neuron activity in both regions increased omissions, SNc DA neuronal activation decreased accuracy and delayed correct response, incorrect response, and reward collection latency, whereas VTA DA neuronal activation did not affect accuracy, correct response latency, and incorrect response latency, and reduced reward collection latency. Thus, the attentional impairments in these groups were mediated through different mechanisms.

VTA DA Neuronal Activation Impairs Sustained Attention and Enhances Behavioral Responsivity

We found that chemogenetic activation of DA neurons in the VTA significantly increased omissions in the 5-CSRTT. This effect persisted during tests with a variable attentional load as a result of shorter or longer SDs. Furthermore, VTA DA neuron activation decreased the latency to collect rewards and to make premature responses, whereas the attentional accuracy was unaffected. These results are in line with a role for mesolimbic DA in the speed and probability of responding, but not in attentional accuracy (Cole and Robbins, 1989). In the present study, we have focused on the role of midbrain DA neuronal activity, whereas the majority of previous studies has investigated DA signaling in striatal and cortical target areas. On the basis of our immunohistochemical results, we presume that VTA DA neuron activation primarily resulted in enhanced DA signaling in the ventral and dorsomedial parts of the striatum. We expect a relatively small contribution of altered mesocortical DA signaling to the observed behavioral effects, as DA levels have been shown to be significantly lower in PFC compared with striatum (10–20-fold difference; Ihalainen et al, 1999; Moghaddam et al, 1990), and we were not able to detect DREADD expression in the PFC. However, future studies should clarify the neurochemical effects of chemogenetic DA neuron activation in target regions of VTA DA neurons. Previous pharmacological studies have shown that infusions of DA-R antagonists or partial agonists into NAc or DMS increased omissions (Besson et al, 2010; Pezze et al, 2007), whereas local DA stimulation in NAc Core and Shell sub-regions did not affect attention in the 5-CSRTT (Economidou et al, 2012; Moreno et al, 2013). In addition, enhanced DA signaling in the medial PFC (mPFC), through reuptake inhibition or D1-R agonism, has been shown to decrease omissions (Agnoli and Carli, 2011; Economidou et al, 2012; Granon et al, 2000). These results are, to some extent, in contrast with our observation that enhanced activity of mesocorticolimbic DA neurons increased the number of omitted trials. However, systemic administration of a D1- or D2-R agonist was shown to have the same effect (Winstanley et al, 2010). Importantly, to fully understand the contribution of DA signaling to omissions in the 5-CSRTT, it is essential to consider the broader behavioral phenotype and its underlying mechanisms. For example, treatment with selective D1- or D2-R antagonists may impair stimulus discrimination, resulting in more omissions as well as decreased accuracy (Pezze et al, 2007). In contrast, enhanced VTA DA neuronal activity may affect other functions, such as behavioral activation (see below), thereby affecting omissions and response latency, while leaving accuracy intact. Future studies are needed to further distinguish the neurochemical and functional mechanisms that determine the effects of DA signaling on attentional behavior.

DA signaling in the NAc has been implicated in approach initiation, especially in anticipation of a reward (Hamid et al, 2015; Ko and Wanat, 2016; Nicola, 2010; Syed et al, 2015). We found that VTA DA neuronal activation reduced the rats’ latency to retrieve rewards, and to make premature responses. In contrast, the latency to make correct or incorrect responses was unaffected. This suggests that, at least under some conditions, enhanced VTA DA neuronal activity promotes rapid action initiation. A fast response initiation may be interpreted as enhanced behavioral activation and/or increased motivation, processes that both involve mesolimbic DA (Nicola, 2010; Robbins and Everitt, 2007; Salamone and Correa, 2012; Wise, 2004). Previously, we have shown that chemogenetic activation of VTA mesolimbic neurons, or local D2-R knockdown, increased motivation to work for sucrose in rats (Boender et al, 2014; de Jong et al, 2015). However, in the present study, we showed that VTA DA neuron activation increased omissions, and did not affect latency to make a correct nose poke, which contradicts a putative increase in motivation. Therefore, we propose that the behavioral profile, including more omissions and faster responses, may reflect effects on behavioral activation rather than motivation. Indeed, chemogenetic activation of midbrain DA neurons or VTA to NAc pathway has been shown to increase locomotor activity (Boekhoudt et al, 2016; Boender et al, 2014; Wang et al, 2013), consistent with a role for increased mesolimbic DA activity in locomotor hyperactivity (Ikemoto, 2002; Kelly et al, 1975). As a result, increased VTA DA neuronal activity likely interferes with the animal’s ability to focus attention on a specific stimulus during a restricted time period, thus impairing sustained attention. Enhanced responsivity to cues may have a dual effect on task performance in the 5-CSRTT. On one hand, it may facilitate the initiation of certain actions, resulting in faster responses. On the other hand, locomotor hyperactivity and responsivity to environmental stimuli that are not relevant for task performance would distract the animal’s attention away from the cue lights, and result in more omissions.

SNc DA Neuronal Activation Impairs Attention and Delays Responsivity

Chemogenetic activation of SNc DA neuronal activity caused significant attentional deficits in the 5-CSRTT, as apparent from increased omissions and reduced accuracy. In addition, response latencies were increased, ie, the rats were slower to make nose-poke responses and to collect the reward. Interestingly, similar results have been observed following lesions of the DMS or DLS, or dorsal striatal DA depletion (Baunez and Robbins, 1999; Rogers et al, 2001). These findings indicate that the nigrostriatal DA pathway is crucially involved in attentional processes, and that disruption of this pathway, either by inhibition or stimulation, may severely affect behavioral performance.

The dorsal striatum is part of a neural circuitry involving frontal cortex and basal ganglia, that regulates divided attention and executive function (Alexander et al, 1986; Dalley et al, 2008; Wimmer et al, 2015). Within this circuitry, the dorsal striatum serves an important role in sensorimotor integration and response control (Nieoullon, 2002; Rogers et al, 2001). The DMS receives projections from the PFC, including medial PFC and anterior cingulate cortex (ACC) (Donoghue and Herkenham, 1986; McGeorge and Faull, 1989). Importantly, lesions or chemogenetic inhibition of these cortical regions have been shown to impair attentional accuracy and response latencies in the 5-CSRTT, similar to the effects of nigrostriatal DA dysfunction (Chudasama et al, 2003; Koike et al, 2015; Muir et al, 1996). In addition, glutamatergic and DAergic signaling in this cortico-striatal circuitry have been shown to interact in the regulation of attentional performance (Agnoli and Carli, 2011; Agnoli et al, 2013). Our results complement these findings by showing that enhanced DA neuronal activity in the SNc also results in impaired attention and response control, comparable to dorsal striatal or prefrontal dysfunction. Previously, it was shown that a selective D1-R agonist or antagonist infused into mPFC could improve or impair attentional accuracy in rats, respectively, depending on low or high baseline performance (Granon et al, 2000). Taken together, these results suggest that there is an optimal level of DA signaling required for accurate task performance. Here, we show a novel finding, indicating that also enhanced DA signaling in the nigrostriatal pathway can be detrimental for attentional performance. We found that SNc DA neuronal activation consistently increased omissions, impaired accuracy, and delayed response latency, irrespective of attentional load. An increase in omissions and response latencies could indicate a reduced motivational state or impaired motor function. However, activation of SNc DA neurons with a low dose of CNO, that did not affect response latencies, was sufficient to impair attention. Furthermore, optogenetic activation of SNc DA neurons has been shown to promote voluntary movements (Barter et al, 2015). Together, this indicates that enhanced SNc DA neuronal activity is sufficient to impair attentional performance, without detrimental effects on motor function or motivation. On the basis of behavioral deficits in patients with Parkinson’s disease, it has been suggested that nigrostriatal dysfunction affects the selection of an appropriate motor response, in particular, when there is uncertainty about the stimulus and its associated response (Nieoullon, 2002). Again, our data suggest that enhanced nigrostriatal DA activity results in a similar phenotype: the animals appear to have difficulty selecting the appropriate response to an unpredictable stimulus, which may result in a slower response, selection of an incorrect motor response, or an omission. We suggest that enhanced SNc DA neuronal activity disrupts DA signaling in dorsal striatal regions, and thereby interferes with sensorimotor integration and the control of appropriate responses to environmental stimuli. However, relatively little is known about the effects of increased nigrostriatal DA activity, and future studies need to elucidate which anatomical and neurochemical aspects are causally related to the observed attentional impairments.

Midbrain DA Neuronal Activation does not Induce Impulsivity

Chemogenetic activation of DA neurons in either the VTA or SNc did not affect impulsivity in the 5-CSRTT. Previous studies have implicated DA in the control of impulsive actions, particularly DA signaling in the (ventral and dorsomedial) striatum (Agnoli et al, 2013; Cole and Robbins, 1989; Economidou et al, 2012; Moreno et al, 2013; Pattij et al, 2007; Pezze et al, 2007). Therefore, we hypothesized that enhancing midbrain DA neuronal activity, in particular of VTA DA neurons that project to NAc or DMS, would increase impulsivity. The discrepancy of our findings with previous reports may be related to several factors, including anatomical sub-region, magnitude of manipulation, and individual differences in impulsivity (Economidou et al, 2012; Moreno et al, 2013; Pezze et al, 2007; Winstanley et al, 2010). Importantly, the effects of CNO depend on endogenous neuronal activity. As mentioned above, neurochemical studies have indicated that phasic DA release in the NAc—related to VTA DA neuron burst firing—is particularly associated with action initiation in anticipation of a reward (Hamid et al, 2015; Roitman, 2004; Syed et al, 2015). This typically occurs in response to a cue that is associated with a reward, such as a light stimulus. When postsynaptic DA signaling in the NAc is pharmacologically elevated, eg, by amphetamine or DA-R agonists, this may mimic the neurochemical situation of ‘action initiation in anticipation of a reward’, and thus the animal is driven to make a response. During the ITI, this would result in a premature response. Indeed, consistent with previous findings (Baarendse and Vanderschuren, 2012; Cole and Robbins, 1989; Van Gaalen et al, 2006), we observed that systemic administration of amphetamine (inducing DA release at synaptic terminals) increased the number of premature responses, and previous studies showed that infusion of a DA-R agonist or a reuptake inhibitor into the NAc or DMS does the same (Agnoli et al, 2013; Moreno et al, 2013; Pezze et al, 2007). CNO, however, is expected to preferentially enhance DA activity when DA neurons are already endogenously active. During the ITI, when the animals are waiting and no particular cues are presented that predict reward availability, there is presumably low baseline DA neuronal activity (Hamid et al, 2015; Syed et al, 2015), although there is evidence for ‘ramping’ activity in anticipation of the stimulus in VTA DA target areas (Donnelly et al, 2015). When the waiting period is longer than expected (prolonged ITI), this may drive the animal to make a response before stimulus onset. We found that, under these high-impulsive conditions, CNO reduced the latency to perform premature responses in both VTA:Dq+ and SN:Dq+ groups, but the total number of premature responses remained unaffected. Our results therefore indicate that enhancing endogenous DA neuron activity in either VTA or SNc may promote action initiation vigor, but is in itself not sufficient to induce impulsive actions.

Summary and conclusion

In this study, we determined the effects of enhanced DA neuronal activity in VTA and SNc on attentional performance and impulsive behavior in rats. We found that VTA DA neuronal activation promotes the vigor of goal-directed actions, but also impairs sustained attention. These effects likely result from enhanced behavioral responsivity. On the other hand, SNc DA neuronal activation impaired sustained attention and accuracy, and slowed responsiveness in the task. This may be attributed to disrupted sensorimotor integration, resulting in impaired execution of a stimulus-induced response. Thus, DA neurons in the VTA or SNc support distinct aspects of cognitive performance. Our findings contribute to the understanding of the neural substrates underlying attention deficits and impulsivity, and provide valuable insights to improve treatment of these symptoms in the clinic.

Funding and disclosure

This project was funded by NeuroBasic, Nudge-IT (FP7-KBBE.2013.2.2-01), and ZonMW. The authors declare no conflict of interest.